skin rash in an 55 year old male on metformin since last 8 years
annular erythematous plaques forearm skin rash diabetes



| Test | Purpose |
|---|---|
| KOH scraping | Rule out tinea corporis (most urgent) |
| Fungal culture | Confirm dermatophyte if KOH equivocal |
| Punch biopsy | Confirm GA (palisading granulomas + mucin deposition) vs other |
| FBG / HbA1c | Assess diabetes control — poor control associated with GA |
| Lipid profile | GA associated with dyslipidemia (Fitzpatrick's, p. 597) |
| ANA, anti-Ro/SSA | If SCLE suspected |
| TSH | GA also associated with thyroid disease |
Note: This is a clinical analysis to assist a healthcare provider. Definitive diagnosis requires in-person examination, KOH microscopy, and likely skin biopsy.
First time report what should be done further
| Parameter | Value | Reference | Interpretation |
|---|---|---|---|
| HbA1c | 7.00% | 4.2–5.7% (normal) | Above normal |
| Average Estimated Glucose | 154.20 mg/dL | — | Elevated |
Note: The report shows age 51Y 3M — please verify if this is the same patient as discussed earlier (noted as 55Y).
| Step | Action |
|---|---|
| 1. KOH scraping | Scrape active border of a lesion — must exclude tinea corporis first before any steroid treatment |
| 2. Fungal culture | If KOH equivocal |
| 3. Punch biopsy (4mm) | From the raised active border of an annular lesion — this is the definitive step if KOH is negative |
| Test | Rationale |
|---|---|
| Lipid profile (fasting) | GA strongly associated with dyslipidemia; also important in T2DM |
| TSH | GA associated with thyroid dysfunction |
| ANA, anti-Ro/SSA | Rule out drug-induced or idiopathic SCLE |
| CBC | Rule out lymphoma-associated GA (less likely but important in adult-onset generalized GA) |
| Serum creatinine / eGFR | Baseline renal function on long-term metformin |
| Vitamin B12 | Metformin × 8 years causes B12 malabsorption in ~30% of patients — can cause neuropathy and other systemic effects |
| Management | Details |
|---|---|
| Topical clobetasol under occlusion | First-line for localized GA |
| Intralesional triamcinolone acetonide (10 mg/mL) | For persistent/thicker lesions |
| Optimize glycemic control | Already at goal (7.0%) — maintain |
| Reassurance | Localized GA often self-resolves in 1–2 years |
| Monitor for generalized spread | Generalized GA warrants more aggressive workup |
This analysis is intended to assist a clinician. Definitive management requires in-person evaluation and histopathologic confirmation.